AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11840364
Drug: Typical dialysis
RxNorm normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical dialysis dose (equilibrated Kt/V = 1.30 +/- 0.22)
Trial: 10920945
Drug: Intra-arterial chemotherapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial chemotherapy via implanted drug delivery system (DDS), administered once every 1 or 2 weeks (Group A)
Trial: 10920945
Drug: One bolus
RxNorm normalized name: PHENYLBUTAZONE 1 g ORAL TABLET [Phenylbutazone Boluses]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One bolus arterial infusion chemotherapy, administered once every month (Group B)
Trial: 2685707
Drug: Timolol treatment
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol treatment (TT)
Trial: 790537
Drug: 0.5% chlorhexidine-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% chlorhexidine-containing gel
Trial: 28528348
Drug: Home oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home oxygen plus home NIV (median oxygen flow rate, 1.0 L/min; inspiratory positive airway pressure of 24 cm H2O; expiratory positive airway pressure of 4 cm H2O; backup rate of 14 breaths/minute)
Trial: 28528348
Drug: Home oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home oxygen alone (median oxygen flow rate, 1.0 L/min)
Trial: 12723055
Drug: Elman network
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elman network for dosage prediction
Trial: 11206597
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg daily for 12 weeks or 25 mg daily for 10 weeks)
Trial: 8692558
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin
Trial: 6647203
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral labetalol
Trial: 6647203
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intramuscular hydralazine
Trial: 30314978
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg/d
Trial: 23228503
Drug: AG200-15 Agile
RxNorm normalized name: AGIL-FA
DrugBank: AGIL-FA (DB16973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG200-15 Agile Patch applied to the lower abdomen
Trial: 23228503
Drug: AG200-15 Agile
RxNorm normalized name: AGIL-FA
DrugBank: AGIL-FA (DB16973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG200-15 Agile Patch applied to the buttock
Trial: 23228503
Drug: AG200-15 Agile
RxNorm normalized name: AGIL-FA
DrugBank: AGIL-FA (DB16973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG200-15 Agile Patch applied to the upper torso
Trial: 23228503
Drug: AG200-15 Agile
RxNorm normalized name: AGIL-FA
DrugBank: AGIL-FA (DB16973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG200-15 Agile Patch (all sites)
Trial: 20003064
Drug: Infant milk
RxNorm normalized name: Infant milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant milk formula supplemented with 6 g/l short‐chain galacto‐ and long‐chain fructo‐oligosaccharides (scGOS/lcFOS, ratio 9:1)
Trial: 17030757
Drug: Dopamine agonist
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonist nontreated group (Control)
Trial: 3690807
Drug: Single-agent metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent metoclopramide (2 mg/kg x 4)
Trial: 3690807
Drug: Combination metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination metoclopramide and dexamethasone
Trial: 31665898
Drug: PRP injection
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP injection into the muscle and skin layers immediately after wound closure
Trial: 31665898
Drug: No PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No PRP injection (Control)
Trial: 29958267
Drug: Lenalidomide in
RxNorm normalized name: Product containing lenalidomide in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide in combination with dexamethasone
Trial: 29958267
Drug: Bortezomib in
RxNorm normalized name: bortezomib Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib in combination with dexamethasone
Trial: 25247709
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose MQ (15 mg/kg)
Trial: 19633693
Drug: Topical tranilast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tranilast and artificial tears (q.i.d.)
Trial: 19633693
Drug: Topical artificial
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical artificial tears, sodium hyaluronate, and vitamin A
Trial: 17432645
Drug: Congrong Tongbian
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Congrong Tongbian Oral Liquid (control group)
Trial: 16115944
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (irinotecan/high-dose 5-fluorouracil/leucovorin) combined with vaccinations using CEA-derived CAP-1 peptide with adjuvants (CAP-1/granulocyte macrophage colony-stimulating factor/interleukin-2, CAP-1/dSLIM/IL-2, CAP-1/IL-2) for three cycles followed by weekly vaccinations until progression of disease.
Trial: 16115944
Drug: Vaccination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination treatment
Trial: 8804877
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid 20 mg/kg/day for 6 months
Trial: 6142645
Drug: Prazosin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (0.5 mg three times a day, titrated to a maximum dose of 12 mg per day)
Trial: 6142645
Drug: Propranolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (10 mg three times a day, titrated to a maximum dose of 120 mg per day)
Trial: 25306749
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (comparison group)
Trial: 23180157
Drug: HPV6/11/16/18 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV6/11/16/18 vaccine
Trial: 17371782
Drug: Generic simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic simvastatin 20-40 mg
Trial: 6318545
Drug: Soy hulls
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy hulls (26 g daily)
Trial: 6318545
Drug: Corn bran
RxNorm normalized name: CORN BRAN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn bran (52 g daily)
Trial: 6318545
Drug: Apple powder
RxNorm normalized name: Nutricia SHS Phlexy-10 Black Currant/Apple Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple powder (52 g daily)
Trial: 25022824
Drug: Medication education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication education group (group I)
Trial: 25022824
Drug: Medication education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication education with behavioral intervention group (group II)
Trial: 20375696
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (pressure therapy + silicone gel sheeting)
Trial: 20375696
Drug: Pressure therapy
RxNorm normalized name: AerobiKA Oscillating Positive Expiratory Pressure Therapy System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure therapy (PG)
Trial: 20375696
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel sheeting (SGS)
Trial: 8535536
Drug: Beta-receptor blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-receptor blockers and/or diuretics
Trial: 8535536
Drug: Calcium antagonists,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists, alpha 1 blockers, and ACE inhibitors
Trial: 2227079
Drug: Nimesulide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide (100 mg rectally, administered one to three times daily for a mean period of 2.5 days)
Trial: 2227079
Drug: Dipyrone (controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone (controlled group, administered one to three times daily for a mean period of 2.5 days)
Trial: 24983295
Drug: Modified constraint‐induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified constraint‐induced movement therapy (CIMT)
Trial: 24983295
Drug: Hand‐arm bimanual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand‐arm bimanual intensive therapy (HABIT)
Trial: 24654314
Drug: MP29-02 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MP29-02 (1 spray/nostril bid)
Trial: 24654314
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) nasal spray (2 sprays/nostril qd)
Trial: 21271793
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 mg plus Ezetimibe 10 mg
Trial: 19432566
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1000 mg) and Vitamin E (400 iu) daily until delivery
Trial: 15257794
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg primaquine
Trial: 11747872
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg LNG taken 12 h apart on day 10 of the cycle (Group A)
Trial: 11747872
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg LNG at the time of serum LH surge (Group B)
Trial: 11747872
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg LNG 48 h after positive detection of urinary LH (Group C)
Trial: 11747872
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg LNG during late follicular phase (Group D)
Trial: 8400610
Drug: Calcium citrate
RxNorm normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium citrate (CC)
Trial: 3546949
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CTX) plus BCG treatment
Trial: 20012877
Drug: Combined parent
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined parent training and child treatment (PT + CT)
Trial: 15961987
Drug: Xenadrine RFA
RxNorm normalized name: Xenazine
DrugBank: Tetrabenazine (DB04844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xenadrine RFA (25 mg ephedra alkaloids and 200 mg caffeine)
Trial: 12869911
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide aqueous nasal spray (TAA AQ) 220 microg daily
Trial: 12869911
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 200 microg daily
Trial: 8551406
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg per day oral prednisone for 6 to 12 weeks
Trial: 8551406
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg per day oral prednisone for 6 to 12 weeks
Trial: 1702493
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (cisplatin-based combination chemotherapy)
Trial: 22217192
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg/Losartan 50 mg
Trial: 22217192
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg/Losartan 50 mg
Trial: 22217192
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg/Losartan 100 mg
Trial: 22217192
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg/Losartan 100 mg
Trial: 22217192
Drug: Amlodipine camsylate/Losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine camsylate/Losartan 5 mg/50 mg
Trial: 22217192
Drug: Amlodipine camsylate/Losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine camsylate/Losartan 5 mg/100 mg
Trial: 22217192
Drug: Amlodipine camsylate/Losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine camsylate/Losartan 10 mg/50 mg
Trial: 22217192
Drug: Amlodipine camsylate/Losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine camsylate/Losartan 10 mg/100 mg
Trial: 16259286
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of dietary calcium plus physical activity 30 minutes three times per week
Trial: 16259286
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of calcium citrate plus 500 mg of dietary calcium and physical activity three times per week
Trial: 7479227
Drug: Hemodialysis (HD)
RxNorm normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hemodialysis (HD) treatment using cuprophan dialyzers and acetate containing solution (35 mEq/l), 4 hours, 3 times weekly.
Trial: 7479227
Drug: Hemodialysis (HD)
RxNorm normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hemodialysis (HD) treatment (group I with hypotensive episodes).
Trial: 7479227
Drug: Hemodialysis (HD)
RxNorm normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hemodialysis (HD) treatment (group II without hypotensive episodes).
Trial: 19303012
Drug: Budesonide (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (9 mg/d) for 6 weeks
Trial: 19303012
Drug: Open-label budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Open-label budesonide (9 mg/d) for 6 additional weeks after placebo
Trial: 3418376
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no BCG therapy)
Trial: 28318077
Drug: No sound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No sound therapy intervention (Control)
Trial: 26024727
Drug: Lenalidomide 10
RxNorm normalized name: lenalidomide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 10 mg/day for 9 days
Trial: 23011321
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg FC + hCRH
Trial: 23011321
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg FC + hCRH
Trial: 23011321
Drug: 0.075 mg
RxNorm normalized name: mestranol 0.075 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075 mg FC + hCRH
Trial: 23011321
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg FC + hCRH
Trial: 23011321
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg FC + placebo
Trial: 23011321
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg FC + placebo
Trial: 23011321
Drug: 0.075 mg
RxNorm normalized name: mestranol 0.075 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075 mg FC + placebo
Trial: 23011321
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg FC + placebo
Trial: 18261121
Drug: AstraTech implants
RxNorm normalized name: CATHETER,COUDE LOFRIC 10FR ASTRATECH #961040
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AstraTech implants
Trial: 11029681
Drug: Antidepressants (tricyclics,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (tricyclics, selective serotonin reuptake inhibitors, S-adenosylmethionine)
Trial: 8233289
Drug: 0.4 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg BW IVIG
Trial: 8233289
Drug: 0.8 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g/kg BW IVIG
Trial: 3157346
Drug: Aztreonam, 1
RxNorm normalized name: Aztreonam, 1 g injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam, 1 g intramuscularly
Trial: 3157346
Drug: Spectinomycin, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectinomycin, 2 g intramuscularly
Trial: 25269896
Drug: Platelet function
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet function monitoring guided antiplatelet therapy (adjusted aspirin to 200 mg/d if AA-induced IPA <50%, adjusted clopidogrel to 150 mg/d if ADP-induced IPA <30%)
Trial: 25269896
Drug: Conventional dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dual antiplatelet therapy (standard treatment)
Trial: 23217188
Drug: MAKS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAKS therapy (motor stimulation, practice of activities of daily living, cognitive stimulation), 2 hours, 6 days a week for 12 months.
Trial: 29249224
Drug: MAKS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAKS therapy
Trial: 23217188
Drug: MAKS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAKS therapy and Control group
Trial: 18262450
Drug: Oxycodone-gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxycodone-gabapentin
Trial: 15984630
Drug: Tazarotene cream
RxNorm normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene cream 0.05% and 0.1%
Trial: 12906339
Drug: Monolithic osmotic
RxNorm normalized name: Ez2go Osmotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monolithic osmotic tablet system (MOTS) containing nifedipine, 30 mg
Trial: 12906339
Drug: Commercial Adalat
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial Adalat osmotic tablet system containing nifedipine, 30 mg
Trial: 1527273
Drug: Psychotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychotherapy without active medication
Trial: 30783259
Drug: Fluoxetine (oral)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (oral) for 3 months
Trial: 22694905
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy plus D-cycloserine (DCS)
Trial: 22694905
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy plus placebo
Trial: 18648963
Drug: Acupuncture (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (twice weekly for 6 weeks)
Trial: 8517172
Drug: 5‐HT reuptake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐HT reuptake inhibitors
Trial: 2948737
Drug: Methoxamine infusion
RxNorm normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methoxamine infusion
Trial: 2948737
Drug: Thymoxamine infusion
RxNorm normalized name: thymoxamine hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoxamine infusion
Trial: 20691795
Drug: Disease-modifying anti-rheumatic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease-modifying anti-rheumatic drug treatment
Trial: 18647806
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pegvisomant (PEG‐V)
Trial: 31961448
Drug: Thresholds of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thresholds of TNE identified from compliant groups at each dose level
Trial: 30488542
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg weekly for 16 weeks
Trial: 29430253
Drug: High-dose Shen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Shen Guo Lao Nian Granule (SGLNG)
Trial: 29430253
Drug: Middle-dose Shen
RxNorm normalized name: wheat middlings extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle-dose Shen Guo Lao Nian Granule (SGLNG)
Trial: 29430253
Drug: Low-dose Shen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Shen Guo Lao Nian Granule (SGLNG)
Trial: 23988786
Drug: 2.3 mg
RxNorm normalized name: menthol 2.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.3 mg kg(‐1) body mass of pseudoephedrine